PharmaEngine's Pancreatic Cancer Drug Seeks Approval in Europe

PharmaEngine of Taiwan announced that its licensing partner, Merrimack Pharma of Boston, and its sublicensing partner, Baxter International, have applied for European marketing approval of MM-398, a liposome-encased form of irinotecan. The drug is indicated to treat metastatic pancreatic cancer in patients previously treated with gemcitabine. PharmaEngine retains rights to the drug in Taiwan, but out-licensed the global rights (ex-Taiwan) to Merrimack in 2011 for $10 million upfront and $210 million in milestones, plus royalties. More details.... Stock Symbols: (TWO:4162) (NSDQ: MACK) (NYSE: BAX) Share this with colleagues: // //